[Special Stock] Medytox Rises as US ITC Lawsuit Turns Favorable
[Asia Economy Reporter Geum Boryeong] Medytox is showing strong performance on the 4th following news that a lawyer affiliated with the U.S. International Trade Commission (ITC) gave an opinion favorable to Medytox in the ITC trial concerning botulinum strains involving Medytox and Daewoong Pharmaceutical.
As of 1:56 PM on the day, Medytox's stock price recorded 297,100 KRW, up 21.81% (53,200 KRW) compared to the previous session.
Medytox announced on the 4th that during the U.S. ITC trial held from the 4th to 7th of last month (local time) in Washington DC regarding the theft of botulinum strains and manufacturing technology, an ITC staff attorney submitted an opinion to the tribunal stating, "We fully agree that Daewoong Pharmaceutical is using Medytox's botulinum strain."
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- "To Get Revenge on Ex-Girlfriend" US McDonald's Manager Spits on French Fries
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
The ITC staff attorney acts as a third party designated by the ITC tribunal, reviewing all evidence presented by both the plaintiff and defendant and providing a neutral opinion.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
